NCT06969833 Prospective Clinico-biological Database of Patients With Ovarian and/or Peritoneal and/or Fallopian Tube Carcinoma
| NCT ID | NCT06969833 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Centre Oscar Lambret |
| Condition | Cancer of the Ovary |
| Study Type | INTERVENTIONAL |
| Enrollment | 371 participants |
| Start Date | 2025-06-27 |
| Primary Completion | 2032-06-27 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 371 participants in total. It began in 2025-06-27 with a primary completion date of 2032-06-27.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Cancer of the ovary and/or peritoneum and/or fallopian tube have a very poor prognosis, and require the implementation of collaborative research tools and new innovative therapies. The main objective of this study is to implement prognostic model of overall survival on patients included prospectively as part of the initial treatment of advanced ovarian and/or peritoneum, and/or fallopian tubes carcinoma (this cohort corresponds to the "Turquoise" care pathway of the Oscar Lambret Center) regardless of the treatment carried out,, integrating both patient's and tumor's characteristics. A clinical and biological database is implemented for this purpose. 371 patients will be recruited over a 5-year period at the Oscar Lambret Center. The active participation of each patient will be 2 years (from the date of pre-registration until the end of study participation, defined by the date of the last intervention specific to the research), then the data from standard care and survival data will be collected until the last follow-up of the last patient, 2 years after the last pre-registration.
Eligibility Criteria
Eligibility criteria for pre-registration: * Patient aged 18 or over * Informed consent warranted * Patient affiliated to a social security regimen * Suspected diagnosis of advanced and invasive ovarian cancer and/or primary peritoneal cancer and/or fallopian tube cancer (IIB to IV FIGO stages) * Pre-registration during standard care at the Oscar Lambret Centre, from diagnosis and before confirmation of definitive FIGO stage Non eligibility criteria for pre-registration: * Patient deprived of liberty or under curatorship or guardianship * Refusal to participate Inclusion criteria: • Confirmed diagnosis of advanced and invasive ovarian cancer and/or primary peritoneal cancer and/or fallopian tube cancer (IIB to IV FIGO stages) Exclusion criteria: • Dismissed diagnosis of advanced and invasive ovarian cancer and/or primary peritoneal cancer and/or fallopian tube cancer , or other type of cancer
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06969833 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Cancer of the Ovary. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06969833 currently recruiting?
Yes, NCT06969833 is actively recruiting participants. Contact the research team at promotion@o-lambret.fr for enrollment information.
Where is the NCT06969833 trial being conducted?
This trial is being conducted at Lille, France.
Who is sponsoring the NCT06969833 clinical trial?
NCT06969833 is sponsored by Centre Oscar Lambret. The trial plans to enroll 371 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.